Key highlights
- 1The menopause care (femtech) market is expected to reach USD 32 billion by 2036, at a CAGR of 9.5% from 2026 to 2036, driven by non-hormonal therapies, digital care, and rising awareness.
- 2Non-hormonal drugs are a breakthrough. Fezolinetant (Veozah), the first neurokinin-3 receptor antagonist, was approved in 2023, and elinzanetant, a dual NK1 and NK3 antagonist, was approved as a further non-hormonal option, expected in the US around November 2025.
- 3Strong efficacy without hormones. Elinzanetant's phase 3 trials showed about a 74% reduction in moderate-to-severe vasomotor symptoms by week 12, with improvements in sleep, offering hormone-free symptom management.
- 4Investment is surging. Investors deployed about USD 1.7 billion in menopause-focused companies from 2020 through 2025, with venture capital over 80% of deal volume concentrated on technology-supported virtual clinics.
- 5Digital clinics improve access. Virtual menopause clinics such as Midi Health, Maven and others expand access to specialist care that has historically been hard to obtain.
- 6A large, under-served population. The global menopause market is worth an estimated USD 10 billion to USD 15 billion and could grow around 8% to 10% annually, reflecting a large, long-neglected population.
- 7Key companies include Astellas Pharma, Bayer AG, Midi Health, Maven Clinic, and Evernow.
Report Overview
The menopause care (femtech) market covers products and services for perimenopause and menopause, spanning hormone therapy, non-hormonal drugs, digital and telehealth care, supplements and over-the-counter products, and devices, addressing vasomotor, genitourinary, mood, sleep and bone symptoms. General women's health outside menopause, and unrelated pharmaceuticals, are outside the scope except as context. Menopause care is a long-neglected area being transformed by new therapies, digital access and investment. Demand is shaped by the aging female population, awareness, non-hormonal innovation, and femtech investment. This report examines the size, drivers, offerings, treatment types, care delivery, pricing, regions, competition, recent developments, and outlook of the market, and provides recommendations. Sizing is built bottom-up from therapeutics, digital care, supplements and devices by offering, treatment type and region, and reflects menopause care products and services.
Market dynamics
Drivers
- 01The aging female population is a primary driver as a large and growing number of women reach perimenopause and menopause and seek care for symptoms that were long neglected.
- 02Destigmatization and awareness are strong drivers as public and workplace conversation about menopause grows, encouraging women to seek treatment and companies to invest.
- 03Non-hormonal drug innovation is a driver as the neurokinin antagonists fezolinetant and elinzanetant provide the first targeted non-hormonal treatments for hot flashes, expanding options for women who cannot or prefer not to use hormones.
- 04Femtech investment and workplace attention are drivers as about USD 1.7 billion flowed into menopause companies from 2020 to 2025 and employers add menopause benefits.
Opportunities
- 01Non-hormonal therapeutics are a leading opportunity as neurokinin antagonists and other non-hormonal drugs address a large unmet need for women avoiding hormones, with strong efficacy.
- 02Virtual menopause clinics are a major opportunity as telehealth expands access to specialist menopause care that is hard to obtain, attracting most femtech investment.
- 03Supplements and over-the-counter products are an opportunity for symptom relief and wellness, though evidence varies.
- 04Employer and workplace benefits are an opportunity as companies add menopause support to retain and support women.
Trends
- 01Non-hormonal breakthroughs are a defining trend as fezolinetant and elinzanetant transform hot-flash treatment with targeted non-hormonal drugs.
- 02The rise of virtual clinics is a trend as telehealth platforms improve access to menopause care.
- 03Destigmatization is a trend as awareness grows in public discourse and the workplace.
- 04Investment growth is a trend as capital flows into menopause therapeutics and care delivery.
Report Summary
| Base Year | 2025 |
|---|---|
| Forecast Period | 2026-2036 |
| Market Size (2025) | USD 12 billion |
| Market Size (2026) | USD 13.1 billion |
| Market Size (2036) | USD 32 billion |
| CAGR (Value) | 9.5% (2026-2036) |
| Format | PDF & Excel |
| Segments Covered | By Offering: Therapeutics, Digital & Telehealth Care, Supplements & OTC, Devices. By Treatment Type: Hormone Therapy, Non-Hormonal Drugs, Supplements, Vaginal/GSM. By Care Delivery; By Region. |
| Geographies Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Companies | Astellas Pharma, Bayer AG, Midi Health, Maven Clinic, Evernow, Peppy, Elektra Health, Organon, Theramex, Hims & Hers Health, Other Companies |
Segmental analysis
By Offering
- Therapeutics hold the largest share at about 55% of the market in 2026, with the remaining share divided across digital and telehealth care, supplements and over-the-counter products, and devices.
- Therapeutics including hormone therapy and non-hormonal drugs, are the largest offering because they are the core medical treatment for menopausal symptoms and include the new non-hormonal medicines.
- Digital and telehealth care including virtual menopause clinics, is a fast-growing offering that expands access and attracts most investment.
- Supplements and over-the-counter products serve symptom relief and wellness.
- Devices including cooling and other symptom-management products, complete the segment.
The dominance of therapeutics reflects the central role of medical treatment, while digital care grows fastest.
By Treatment Type
- Hormone therapy holds the largest share at about 45% of the market in 2026, with the remaining share divided across non-hormonal drugs, supplements, and vaginal and genitourinary treatments.
- Hormone therapy or menopausal hormone therapy, remains the largest and most effective treatment for many symptoms and is widely used.
- Non-hormonal drugs chiefly the neurokinin antagonists fezolinetant and elinzanetant, are the fastest-growing type, providing targeted options for women avoiding hormones.
- Supplements address symptoms with varying evidence.
- Vaginal and genitourinary treatments address genitourinary symptoms of menopause.
The dominance of hormone therapy reflects its efficacy and use, while non-hormonal drugs grow fastest as a breakthrough.
By Care Delivery
- Traditional care through physicians and gynecologists, holds the largest share, as most care is still delivered in person, though menopause has been under-served.
- Telehealth and virtual clinics are the fastest-growing channel at about 30% of the market in 2026, expanding access to specialist menopause care and attracting most femtech investment.
- Retail and pharmacy deliver supplements over-the-counter products and prescriptions.
The growth of telehealth and virtual clinics reflects the improvement in access they provide, while traditional care remains the largest channel and retail serves products.
Geographic analysis
North America Menopause Care (Femtech) Market
North America is the largest regional market driven by a large population of women reaching menopause, strong awareness and destigmatization, the approval and launch of non-hormonal drugs, and the concentration of femtech investment and virtual clinics. The region leads in menopause care innovation and hosts many virtual clinics and the launch of new therapies. Strong awareness, investment and drug approvals make North America the leading market.
Europe Menopause Care (Femtech) Market
Europe is a major market with growing awareness, workplace menopause policies in markets such as the United Kingdom, strong hormone-therapy use, and adoption of new non-hormonal drugs. European attention to menopause in the workplace and healthcare, and companies such as Peppy and Theramex, support demand. Europe is a leading and growing market with strong workplace and healthcare focus.
Asia-Pacific and Rest of World
Asia-Pacific is a large and fast-growing market with a vast population of women reaching menopause, growing awareness, and rising demand for care, though menopause care is less developed in many markets. The rest of the world adds growing demand as awareness and access improve. These regions add strong growth potential from a large, under-served population as awareness and care expand.
Pricing Analysis
Pricing in menopause care spans prescription drugs, digital subscriptions, and retail products, and is shaped by reimbursement. Non-hormonal drugs are premium-priced as novel branded medicines, hormone therapy varies from low-cost generics to branded products, virtual clinics charge subscriptions or visit fees, and supplements are retail-priced. Reimbursement and insurance coverage significantly shape access and pricing. Several factors set price. Therapeutic type is central, as novel non-hormonal branded drugs are priced well above generic hormone therapy. Reimbursement and coverage matter, as insurance and employer coverage shape access and out-of-pocket cost, and gaps limit access. Care delivery affects price, with virtual clinics charging subscription or visit fees. Supplements are priced at retail with wellness positioning. Employer sponsorship affects access.
The trajectory of pricing depends on drug pricing and reimbursement, digital care models, and coverage, and reimbursement gaps for novel drugs and digital care are a key constraint on access even as demand grows.
Competitive landscape
The market is served by pharmaceutical companies, digital menopause clinics, and product companies. Astellas Pharma markets Veozah, the fezolinetant neurokinin-3 antagonist, and Bayer developed elinzanetant, the dual NK1 and NK3 antagonist, the leading non-hormonal drugs. Hormone-therapy makers including Organon and Theramex supply menopausal hormone therapy. Digital menopause clinics Midi Health, Maven Clinic, Evernow, Peppy and Elektra Health provide telehealth menopause care, and Hims and Hers and others offer menopause care and products, alongside supplement and device companies.
Competition turns on clinical efficacy and safety, access and care delivery, brand and awareness, and reimbursement, and the market combines pharmaceutical companies with breakthrough drugs, digital clinics expanding access, and product companies. Non-hormonal innovation, digital access and awareness favour companies with effective therapies, strong care delivery and trusted brands, and Astellas and Bayer lead in non-hormonal drugs while digital clinics lead in access. The field is dynamic and well-funded, with pharmaceutical innovation and a wave of femtech care-delivery companies reshaping menopause care.
Voice of Customer
Women have been under-served in menopause care for decades, and telehealth lets us reach them with specialist care and the full range of options, including the new non-hormonal drugs for those who cannot or prefer not to use hormones. The non-hormonal medicines are a real advance for hot flashes, and access and reimbursement are the main barriers we help patients navigate.
Menopause specialist, virtual clinic (North America):
We added menopause support to our benefits because it affects many of our employees and their work, and it helps us retain and support experienced women. We offer access to specialist care and information, and awareness has grown enormously, though coverage of treatments and the cost of newer drugs are considerations.
Benefits director, employer (Europe):
I struggled to get help for my symptoms until I found a virtual menopause clinic, which gave me options I did not know existed, including a non-hormonal medication for my hot flashes. Access to knowledgeable care made the difference, and I wish it had been available and covered sooner.
Perimenopausal woman, patient (North America):
Analyst perspective
The menopause care femtech market is a growing, transforming market addressing a large, long-neglected population. Menopause care was under-served for decades, and it is now being transformed on two fronts: pharmaceutical innovation, with the neurokinin antagonists fezolinetant and elinzanetant providing the first targeted non-hormonal treatments for hot flashes with strong efficacy, and care delivery, with virtual menopause clinics improving access and attracting most of the roughly USD 1.7 billion invested in menopause companies from 2020 to 2025. Growing awareness and destigmatization, an aging female population, and workplace attention drive demand, and the global market is estimated at USD 10 billion to USD 15 billion growing at around 8% to 10%. Pharmaceutical companies, digital clinics and product companies compete.
The honest considerations are reimbursement and access, the maturity of some offerings, and evidence. The central barrier is access: novel non-hormonal drugs are premium-priced and reimbursement is uneven, virtual-clinic care may not be covered, and access varies widely by market and insurance, so the large unmet need does not translate automatically into paid care, and coverage will shape the pace of growth. The femtech care-delivery segment, while attracting most investment, is young, and the sustainability of virtual-clinic business models and the consolidation of a crowded field bear watching. Supplements and some products have variable clinical evidence, and hormone therapy carries a complex safety history that affects perceptions. The market should be assessed on reimbursement and access, the adoption of non-hormonal drugs and digital care, and the sustainability of care-delivery models rather than on the unmet-need narrative alone, and non-hormonal innovation, digital access and awareness support steady growth, with reimbursement, access and business-model maturity the key variables.
Key Strategic Developments
- 2023: Fezolinetant (Veozah), the first neurokinin-3 receptor antagonist, was approved for moderate-to-severe hot flashes, the first targeted non-hormonal treatment for menopausal vasomotor symptoms.
- 2025: Elinzanetant, a dual NK1 and NK3 receptor antagonist, was approved as a non-hormonal therapy for menopausal vasomotor symptoms, expected in the US around November 2025, with phase 3 trials showing about a 74% reduction in symptoms by week 12.
- 2020-2025: Investors deployed about USD 1.7 billion in menopause-focused companies, with venture capital over 80% of deal volume concentrated on technology-supported virtual clinics.
- 2024-2026: Virtual menopause clinics such as Midi Health, Maven, Evernow and Peppy expanded access to specialist menopause care and grew rapidly.
- 2024-2026: Awareness and workplace attention to menopause grew, with employers adding menopause benefits, particularly in markets such as the United Kingdom.
Strategic Recommendations
For pharmaceutical and care companies
The priority is to expand access and reimbursement and to build effective, trusted therapies and care, because the large unmet need is real but access and coverage are the barriers. Pharmaceutical companies should pursue reimbursement and access for non-hormonal drugs, digital clinics should build sustainable, covered care models and demonstrate outcomes, and product companies should support claims with evidence. Serving the under-served population, partnering with employers and health plans, and building trusted brands strengthen the position.
For employers and health plans
The recommendation is to cover and support menopause care, given its impact on women and workforces, including access to specialist care and treatments. For providers, expanding menopause expertise and offering the full range of options, including non-hormonal drugs, improves care. For policymakers, supporting coverage and awareness advances access. For investors, this is a growing market addressing a large unmet need, to evaluate on reimbursement and access, adoption of non-hormonal drugs and digital care, and the sustainability of care-delivery models rather than on the unmet-need narrative alone, recognising that non-hormonal innovation, digital access and awareness support steady growth while reimbursement, access and business-model maturity are the key variables.
Sustainability impact
Women's Health and Wellbeing
Menopause care improves the health, wellbeing and quality of life of women through a major life transition. Menopause care supports women's health.
By treating symptoms and supporting women through menopause, care improves health, wellbeing and quality of life for a large population during a significant and long-neglected life transition, an important health and social contribution.
Access and Equity
Virtual clinics and awareness expand access to menopause care for an under-served population. Menopause care supports access.
By improving access to specialist care through telehealth and raising awareness, menopause femtech helps address the long under-service of women's menopause health, supporting equity, though access still depends on cost and coverage.
Workforce Participation
Supporting women through menopause helps them stay and thrive at work, supporting workforce participation. Menopause care supports the workforce.
By helping women manage menopause symptoms, care and workplace support help experienced women remain and thrive in the workforce, supporting workforce participation and reducing the loss of talent and experience.
Evidence, Access, and Responsible Care
The benefit of menopause care depends on evidence-based treatment, responsible claims, and equitable access. Menopause care requires responsible provision.
By spanning drugs, digital care and supplements of varying evidence, menopause care delivers its benefit through evidence-based treatment, responsible claims and equitable, affordable access, so responsible provision and coverage are central to its value.
Table of contents
14 chapters · 235 pages · click to expandFrequently asked questions
The menopause care (femtech) market was valued at USD 12 billion in 2025 and is projected to reach USD 32 billion by 2036, growing from USD 13.1 billion in 2026, at a CAGR of 9.5% from 2026 to 2036, driven by non-hormonal therapies, digital care, and rising awareness.